September 24, 2013

Data Show Sanofi’s Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled

Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combination with Basal Insulin

 

Data Show Sanofi’s Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled
Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combination with Basal Insulin

Paris, France – September 24, 2013 – Sanofi (EURONEXT : SAN and NYSE : SNY) announced today new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia® (lixisenatide), when added to basal insulin, were greatest in patients with type 2 diabetes who had well-controlled baseline fasting plasma glucose (FPG). These findings are consistent with the efficacy profile of Lyxumia, which shows a clinical and statistically significant reduction in HbA1c across different patient populations.